Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
1 clinical trials · Condition
◉ Watch Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
| Record | Firm | Date |
|---|---|---|
| Tucatinib+Trastuzumab+Eribulin in HER2+ MBC (NCT05458674) | Criterium, Inc. | 2024-01-30 |
Track Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.